دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Vein Graft Use and Long-Term Survival Following Coronary Bypass Grafting
Emily Shih, MD,a,b John J. Squiers, MD, a,c Jasjit K. Banwait, P HD, b Michael J. Mack, MD, b,c Mario Gaudino, MD, d William H. Ryan, MD,c J. Michael DiMaio, MD,b,c Justin M. Schaffer, MD
doi : 10.1016/j.jacc.2022.11.054
Volume 81, Issue 8, 28 February 2023, Pages 713-725
Although placement of at least 1 arterial graft during coronary artery bypass grafting (CABG) has a proven survival benefit, it is unknown what degree of revascularization with saphenous vein grafting (SVG) is associated with improved survival.
Saphenous Vein Grafts for Coronary Surgery: More May Be Less
Marcus Flather, MBBS, MBA, Suprateeka Talukder, MBBS, MR ES
doi : 10.1016/j.jacc.2022.11.055
Volume 81, Issue 8, 28 February 2023, Pages 726-728
Outcomes of Simultaneous Heart and Kidney Transplantation
Shinobu Itagaki, MD, MSC ,a Nana Toyoda, MD, P HD, a Noah Moss, MD, b Donna Mancini, MD, b Natalia Egorova, PHD, c Takahisa Mikami, MD, d Erick Sun, MD,a Yuki Bekki, MD, e Gregory Serrao, MD,b Anuradha Lala, MD, b Percy Boateng, MD, a David H. Adams, MD,a Anelechi C. Anyanwu, MD
doi : 10.1016/j.jacc.2022.11.053
Volume 81, Issue 8, 28 February 2023, Pages 729-740
Simultaneous heart-kidney transplantation has been increasingly performed in end-stage heart failure patients with concurrent kidney dysfunction despite limited evidence supporting its indications and utility.
Simultaneous Heart-Kidney Transplantation: Balancing Competing Outcomes for Transplant Wait-Listed Patients∗
Andrew Civitello, MD, Ajith Nair, MD
doi : 10.1016/j.jacc.2022.12.010
Volume 81, Issue 8, 28 February 2023, Pages 741-742
Cardiac Damage and Quality of Life After Aortic Valve Replacement in the PARTNER Trials
Philippe Généreux, MD, a David J. Cohen, MD, MS C, b,c Philippe Pibarot, DVM, PHD, d Björn Redfors, MD, PH D, b,e,f Jeroen J. Bax, MD, PH D, g Yanglu Zhao, MD, PH D, h Heather Prince, PH D, h Raj R. Makkar, MD, i Samir Kapadia, MD,j Vinod H. Thourani, MD,k Michael J. Mack, MD, l Tamim M. Nazif, MD,e Brian R. Lindman, MD,m Vasilis Babaliaros, MD,n Mark Russo, MD,o James M. McCabe, MD,p Linda D. Gillam, MD, MPH,a Maria C. Alu, MS, b,e Rebecca T. Hahn, MD,b,e John G. Webb, MD,q Martin B. Leon, MD, b,e Suzanne V. Arnold, MD, MHA
doi : 10.1016/j.jacc.2022.11.059
Volume 81, Issue 8, 28 February 2023, Pages 743-752
The extent of extravalvular cardiac damage is associated with increased risk of adverse events among patients with severe aortic stenosis undergoing aortic valve replacement (AVR).
Options to Improve Quality of Life for Aortic Stenosis: “No Decision About Me, Without Me�∗
Megan Coylewright, MD, MPH,a James L. Januzzi, MD, b Molly Szerlip, MD
doi : 10.1016/j.jacc.2022.12.016
Volume 81, Issue 8, 28 February 2023, Pages 753-755
Short-Term Risk Stratification of Non–Flow-Limiting Coronary Stenosis by Angiographically Derived Radial Wall Strain
Shengxian Tu, P HD, a, * Bo Xu, MBBS, b,c, * Lianglong Chen, MD, PHD, d Huihong Hong, MD,d Zhiqing Wang, MD,a,d Chunming Li, BSC,a Miao Chu, PH D, a Lei Song, MD,b Changdong Guan, MSC, b Bo Yu, MD, e Zening Jin, MD, f Guosheng Fu, MD,g Xuebo Liu, MD,h Junqing Yang, MD,i Yundai Chen, MD,j Junbo Ge, MD, k Shubin Qiao, MD,b William Wijns, MD, PHD, l on behalf of the FAVOR III China Study Group
doi : 10.1016/j.jacc.2022.11.056
Volume 81, Issue 8, 28 February 2023, Pages 756-767
Deferred revascularization of mildly stenotic coronary vessels based exclusively on physiological evaluation is associated with up to 5% residual incidence of future adverse events at 1 year.
Radial Wall Strain and Plato’s Cave: Are Shadows Enough to Get the Truth?∗
Francesco Prati, MD, a,b,c Flavio Giuseppe Biccirè, MDa,
doi : 10.1016/j.jacc.2022.12.014
Volume 81, Issue 8, 28 February 2023, Pages 768-770
Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week
Josephine Harrington, MD, Jonathan P. Piccini, MD, John H. Alexander, MD, Christopher B. Granger, MD, Manesh R. Patel, MD
doi : 10.1016/j.jacc.2022.11.057
Volume 81, Issue 8, 28 February 2023, Pages 771-779
Factor XI/XIa (FXI/FXIa) represents a potential target for improved precision in anticoagulation because it is involved primarily in thrombus formation and plays a much smaller role in clotting and hemostasis.
Editor-in-Chief’s Top Picks From 2022
Valentin Fuster, MD, P HD
doi : 10.1016/j.jacc.2023.01.002
Volume 81, Issue 8, 28 February 2023, Pages 780-841
Too Much, Too Little, Too Late
Edward T.A. Fry, MD, FACC, President, American College of Cardiology
doi : 10.1016/j.jacc.2023.01.007
Volume 81, Issue 8, 28 February 2023, Pages 842-844
Sex Differences in Early Rhythm Control of Atrial Fibrillation in the EAST-AFNET 4 Trial
Isabelle C. Van Gelder, MD, PhD Neda Khalilian Ekrami, MD Katrin Borof, MSc Thomas Fetsch, MD Christina Magnussen, MD Bart A. Mulder, MD, PhD Renate Schnabel, MD, PhD Karl Wegscheider, MSc Michiel Rienstra, MD, PhD
doi : 10.1016/j.jacc.2022.12.011
Volume 81, Issue 8, 28 February 2023, Pages 845-847
Malignant Hypertensive Cardiomyopathy: Definition Matters
Romain Boulestreau, MD Philippe Gosse, MD, PhD Julien Doublet, MD Antoine Cremer, MD, PhD
doi : 10.1016/j.jacc.2022.11.058
Volume 81, Issue 8, 28 February 2023, Pages e57-e58
Reply: Malignant Hypertensive Cardiomyopathy: Definition Matters
Simon B. Ascher, MD, MPH James A. de Lemos, MD MinJae Lee, PhD Jarett D. Berry, MD, MS
doi : 10.1016/j.jacc.2022.12.015
Volume 81, Issue 8, 28 February 2023, Page e59
